Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Клиническое значение растворимого CD40 лиганда у больных ишемической болезнью сердца

Полный текст:

Аннотация

Воспаление и тромбоз играют важную роль в патогенезе различных сердечно-сосудистых заболеваний (ССЗ). Связь развития атеросклероза и острого коронарного синдрома (ОКС) является двусторонней. Одним из механизмов, связывающих воспаление и тромбообразование, является активация сигнальной системы CD40/CD40L. CD40 и CD40 лиганд (CD40L) - трансмембранные гликопротеиды, относящиеся к семейству рецепторов факторов некроза опухоли и семейству факторов некроза опухоли соответственно. CD40 и CD40L экспрессируются различными клетками, в т.ч. клетками атеросклеротической бляшки: В-лимфоцитами, макрофагами/моноцитами, эндотелиальными и гладкомышечными клетками. Недавно к источникам растворимой формы CD40L (sCD40L) были причислены тромбоциты. В исследованиях последних лет изучалось диагностическое и прогностическое значения sCD40L у больных ишемической болезнью сердца (ИБС). Было показано достоверное увеличение уровней sCD40L y больных инфарктом миокарда и нестабильной стенокардией по сравнению с больными стабильной стенокардией напряжения и здоровыми лицами. Прогностическое значение sCD40L изучено у относительно здоровых женщин, а также у больных с ОКС; высокие уровни sCD40L независимо предсказывали увеличение сердечно-сосудистого риска. Повышение уровней sCD40L в плазме связано с развитием рестеноза после баллонной ангиопластики коронарных артерий. Есть данные о повышенных концентрациях sCD40Ly больных сахарным диабетом, с гиперхолестеринемией, острой ишемией мозга, у курильщиков, а также у пациентов с первичной и вторичной легочной гипертензией. sCD40L можно рассматривать, как маркер воспаления и тромбообразования одновременно, а повышение его уровня является фактором риска ССЗ и связано с неблагоприятным прогнозом у больных ИБС.

Об авторах

О. П. Шевченко
Российский государственный медицинский университет на базе Клинической больницы Управления делами Президента РФ. Москва
Россия


О. Ф. Природова
Российский государственный медицинский университет на базе Клинической больницы Управления делами Президента РФ. Москва
Россия


А. О. Шевченко
Российский государственный медицинский университет на базе Клинической больницы Управления делами Президента РФ. Москва
Россия


Список литературы

1. Alderson M.R., Armitage R.J., Tough T.W., et al. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993; 178: 669-74.

2. Armitage R.J., Fanslow W.C., Strockbine L., et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80-2.

3. Aukrust P., Muller F., Ueland T., et al. Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients With Unstable Angina. Circulation 1999; 100: 614-20.

4. Bereczki D., Nagy E.P.l.A., et al. Should Soluble CD40 Ligand Be Measured From Serum or Plasma Samples? Circulation 2002; 106: 2888-93.

5. Biasucci L.M., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 4: 874-7.

6. Biemond B.J., Levi M., Coronel R., et al. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a PAI-1 -neutralizing monoclonal antibody. Circulation 1995;91: 1175-81.

7. Boyle J. J. Association of coronary plaque rupture and atherosclerotic inflammation. J Pathol 1997; 181(1): 93-9.

8. Braunwald E. Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction. Circulation 2003; 108:111-28.

9. Chan F.K., Chun H.J., Zheng L., et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-4.

10. Chew D.P., Bhatt D.L., Sapp S., Topol E.J. Increased mortality with oral platelet glycoprotein Ilb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.Circulation 2001; 103: 201-6.

11. Cipollone F., Ferri C., Desideri G., et al. Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty. Circulation 2003; 108: 2776-82.

12. Cipollone F., Mezzetti A., Porreca E., et al. Association Between Enhanced Soluble CD40L and Prothrombotic State in Hypercholesterolemia. Effects of Statin Therapy. Circulation 2002; 106: 399-402.

13. Cocks B.G., Malefyt R.W., Galizzi J.P., et al. IL-13 induces proliferation and differentiation of human В cells activated by the CD40 ligand. hit Immunol 1993; 5: 657-63.

14. Cushman M., Lemaitre R., Kuller L., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly: the Cardiovascular Health Study. Arterioscler Thromb Vase Biol 1999; 19: 493-8.

15. Damas J.K., Otterdal K., Yndestad A., et al. Soluble CD40 Ligand in Pulmonary Arterial Hypertension. Possible Pathogenic Role of the Interaction Between Platelets and Endothelial Cells. Circulation 2004;110:999-1005.

16. Festa A., DAgostino R.J., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.

17. Fitzgerald D.J., Roy L., Catella F., et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.

18. Freedman J.E. CD40-CD40L and Platelet Function Beyond Hemostasis. Ore Res 2003; 92: 944-6.

19. Freedman J.E., Loscalzo J. Platelet-Monocyte Aggregates Bridging Thrombosis and Inflammation. Circulation 2002; 105: 2130-2.

20. Frohlich M., Imhof A., Berg G., et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9.

21. Frostegard J., Ulfgren A.K., Nyberg P., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Thl) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33-43.

22. Garlichs C.D., Eskafi S., Raaz D., et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86: 649-55.

23. Garlichs C.D., John S., SchmeiBer A., et al. Upregulation of CD40 and CD40 Ligand (CD 154) in Patients With Moderate Hypercholesterolemia. Circulation 2001; 104: 2395-400.

24. Garlichs C.D., Kozina S., Fateh-Moghadam S., et al. Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia. Stroke 2003; 34: 1412-8.

25. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-35.

26. Hayes I.M., Jordan N.J., Towers S., et al. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vase Biol 1998; 18: 397-403.

27. Hakonarson H., Kim C., Whelan R., et al. Bi-directional activation between human airway smooth muscle cells and T lymphocytes: role in induction of altered airway responsiveness. J Immunol 2001; 166: 293-303.

28. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activatoi inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.

29. Harding S.A., Sarma J., Josephs D.H., et al. Upregulation of the CD40/CD40 Ligand Dyad and Platelet-Monocyte Aggregation in Cigarette Smokers. Circulation 2004; 109: 1926-9.

30. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 Ligand in Acute Coronary Syndromes. N Engl J Med 2003; 348: 1104-11.

31. Henn V., Slupsky J.R., Graefe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.

32. Henn V., Steinbach S., Buchner K., et al. The inflammatory reaction of CD40 ligand (CD 154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98:1047-54.

33. Hollenbaugh D., Grosmaire L.S., Kullas C.D., et al. The humanT cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with В cell co-stimulatory activity. EMBO J 1992; 11: 4313-21.

34. Hollenbaugh D., Mischel-Petty N., Edwards C.P., et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995; 182: 33-40.

35. Hostager B.S., Hsing Y., Harms D.E, Bishop G.A. Different CD40 -mediated signaling events requires.distinct CD40 structural features. J Immunol 1996; 157:1047-53.

36. Huo Y., Schober A., Forlow S.B., e tal. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-7.

37. Ikeda H., Takajo Y., Ichiki K., et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995; 92: 1693-6.

38. Inui S., Kaisho T., Kikutani H., et al. Identification of the intracytoplasmic region essential for signal transduction through а В cell activation molecule, CD40. Eur J Immunol 1990; 20: 1747-53.

39. Inwald D.P., McDowall A., Peters M.J., et al. CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism foi Platelet Activation. Ore Res 2003; 92: 1041-8.

40. Johnson B.D., Kip K.E., Marroquin О.С., et al. Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-32.

41. Karmann K., Hughes C.C., Schechner J., et al. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995; 92: 4342-6.

42. Kiener P.A., Moran-Davis P., Rankin B.M., et al. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995; 155: 4917-25.

43. Kinlay S.S., Schwartz G.G., Olsson A.G., et al. Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated Wth High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL). Circulation 2004; 110:386-91.

44. Koenig W.L. wel H., Baumert J., Meisinger С. C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany. Circulation 2004; 109:1349-53.

45. Levi M., ten Cate H. Disseminated intravascular coagulation. N EnglJ Med 1999; 341: 586-92.

46. Levi M., van der Poll T., Buller H.R. Bidirectional Relation Between Inflammation and Coagulation. Circulation 2004; 109: 2698-704.

47. Li D., Liu L., Chen H., et al. LOX-1, an Oxidized LDL Endothelial Receptor, Induces CD40/CD40L Signaling in Human Coronary Artery Endothelial Cells. Arterioscler Thromb Vase Biol 2003; 23: 816-21.

48. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.

49. Libby P., Simon D.I. Inflammation and Thrombosis The Clot Thickens. Circulation 2001; 103: 1718.

50. Lim H.S., Blann A.D., Lip G.Y.S. Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus Relationships to Cardiovascular Disease and Risk Factor Intervention. Circulation 2004; 109: 2524-8.

51. Locksley R., Killeen N., Lenardo M. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.

52. Lutgens E., Cleutjens K.B., Heeneman S., et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 2000; 97: 7464-9.

53. Lutgens E., Gorelik L., Daemen M.J., et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999; 5: 1313-6.

54. Mach F., Schonbeck U., Sukhova G.K., et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-3.

55. Mach F., Schonbeck U., Bonnefoy J-Y., et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396-9.

56. Mach F., Schonbeck U., Sukhova G.K., et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-6.

57. Marx N., Imhof A., Froehlich J., et al. Effect of Rosiglitazone Treatment on Soluble CD40 L in Patients Wth Type 2 Diabetes and Coronary Artery Disease. Circulation 2003; 107: 1954-7.

58. Maseri A., Clanflone D. Inflammation in acute coronary syndromes. Eur Heart J Suppl 2002; 4: 8-12.

59. Massberg S., Brand K., Gruener S., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-96.

60. Michelson A.D., Barnard M.R., Krueger L.A., et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-7.

61. Morris A.E., Remmele R.L.Jr., Klinke R., et al. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem 1999; 274: 418-23.

62. Nannizzi-Alaimo L., Rubenstein M.H., Alves V.L., et al. Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand. Circulation 2002; 105: 2849-54.

63. Paulie S., Ehlin-Henriksson В., Mellstedt H., et al. A p50 surface antigen restricted to human urinary bladder carcinomas and В lymphocytes. Cancer Immunol Immunother 1985; 20: 23-8.

64. Pickup J.C., Mattock M.B., Chusney G.D., et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.

65. Pinchuk L.M., Klaus S.J., Magaletti D.M., et al. Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. J Immunol 1996; 157: 4363-70.

66. Pradhan A.D., LaCroix A.Z., Langer R.D., et al. Tissue Plasminogen Activator Antigen and D-Dimer as Markers for Atherothrombotic Risk Among Healthy Postmenopausal Women. Circulation 2004; 110:292-300.

67. Pullen S.S., Labadia M.E., Ingraham R.H., etal. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 1999; 38: 10168-77.

68. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.

69. Ridker P.M. Inflammation, infection and cardiovackular risk: How good in clinical evidence? Circulation 1998; 97: 1671-4.

70. Ridker P.M., Cook N. Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores. Circulation 2004; 109: 1955-9.

71. Schoenhagen P., Tuzcu E.M., Ellis S.G. Plaque Vulnerability, Plaque Rupture, and Acute Coronary Syndromes. Circulation 2002; 106: 760-2.

72. Schonbeck U., Libby P. CD40 Signaling and Plaque Instability. Circ Res 2001; 89: 1092-103.

73. Schonbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.

74. Schonbeck U., Mach F., Libby P. CD 154 (CD40 ligand). Int J Biochem Cell Biol 2000; 32: 687-93.

75. Schonbeck U., Mach F., Sukhova G.K., et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 1999; 189: 843-53.

76. Schonbeck U., Mach F., Sukhova G.K, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997; 81: 448-54.

77. Schonbeck U., Sukhova G.K., Shimizu K., et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000; 97: 7458-63.

78. Schonbeck U., Vara N., Libby P., et al. Soluble CD40L and Cardiovascular Risk in Women. Circulation 2001; 104: 2266-8.

79. Urbich C., Dernbach E., Aicher A., et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002; 106: 981-6.

80. Varo N., Vicent D., Libby P., et al. Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients. Circulation 2003; 107: 2664-9.

81. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L Risk Prediction After Acute Coronary Syndromes. Circulation 2003; 108: 1049-52.

82. Yellin M.J., Brett J., Baum D., et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med 1995; 182: 1857-64.

83. Zhou L., Stordeur P., de Lavareille A., et al. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 1998; 79: 1025-8.a


Для цитирования:


Шевченко О.П., Природова О.Ф., Шевченко А.О. Клиническое значение растворимого CD40 лиганда у больных ишемической болезнью сердца. Кардиоваскулярная терапия и профилактика. 2006;5(7):101-111.

For citation:


Shevchenko O.P., Prirodova O.F., Shevchenko A.O. Clinical value of soluble CD40 ligand in coronary heart disease patients. Cardiovascular Therapy and Prevention. 2006;5(7):101-111. (In Russ.)

Просмотров: 39


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)